CTI Biopharma have issued the top-line results of the PERSIST-2 study, which you can read here…
Professor Claire Harrison says of the results:
I am very happy to see these positive results for the effectiveness and safety of pacritinib which will now hopefully quickly become more widely available for patients with low blood counts and myelofibrosis.
Pacritinib was put on a full clinical hold by the FDA but hopefully this data will help us to work together to bring the drug to patients in need.
